CFD
INSY

Creative Financial Designs’s Insys Therapeutics, Inc. INSY Stock Holding History

Creative Financial Designs’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30
Closed – – 784
2017
Q4 		$0 Hold
30
– – ﹤0.01% 816
2017
Q3 		$0 Hold
30
– – ﹤0.01% 845
2017
Q2 		$0 Buy
+30
New +$355 ﹤0.01% 863

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Creative Financial Designs's INSY Position: Q1 2018 in Review

Creative Financial Designs sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 30 shares.

Creative Financial Designs first reported a position in INSY in Q2 2017 and held it in 3 quarters. The position peaked at $0 in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Creative Financial Designs reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Creative Financial Designs sold 30 Insys Therapeutics, Inc. shares in Q1 2018.
  • Creative Financial Designs first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Creative Financial Designs's Insys Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Creative Financial Designs's 13F filing for Q1 2018, filed 2 May 2018.